A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.

Pietro IaffaldanoGiuseppe LucisanoTommaso GuerraDamiano PaolicelliEmilio PortaccioMatilde IngleseMatteo FoschiFrancesco PattiFranco GranellaGiovanni RistoriPaola CavallaGiovanna De LucaPaolo GalloPaolo BellantonioAntonio GalloSara MontepietraAlessia Di SapioMarika VianelloRocco QuatraleDaniele SpitaleriRaffaella ClericiValentina Torri ClericiEleonora CoccoVincenzo Brescia MorraGirolama Alessandra MarfiaVincenzo Daniele BocciaMassimo FilippiMaria Pia AmatoMaria Trojanonull null

Published in: Annals of clinical and translational neurology (2024)

Both medications strongly suppress RAW events and, in the short term, the risk of achieving PIRA events, EDSS 4.0 and 6.0 milestones is not significantly different.

Keyphrases

multiple sclerosis
white matter